Remote Myocardial Ischemic Preconditioning in Humans (RemoteMIPH)

Mayo Clinic

Status: Completed

Conditions: Coronary Artery Ischemia

Treatments: Device: Blood pressure cuff; Device: blood pressure cuff

Study type: Interventional

Funder types: Other

Identifiers

NCT00588042

06-005081

Details and patient eligibility

About

Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.

Full description

Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. We will also test the hypotheses that IP diminishes the inflammatory response to PCI, and that higher baseline blood endothelial progenitor cell counts are predictive of a favorable response to IP.

Aim 1: To evaluate whether remote ischemic preconditioning reduces the frequency of myonecrosis (troponin T≥0.03 ng/ml following PCI).

Aim 2: To evaluate whether remote ischemic preconditioning reduces the inflammatory response to PCI (post PCI hsCRP level).

Aim 3: To evaluate whether pre-procedure circulating endothelial progenitor cell counts correlate with the effect of remote ischemic preconditioning on myonecrosis.

Background: Percutaneous coronary intervention (PCI) frequently results in ischemic myonecrosis. Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.

Aims: The aims of the study are to assess in patients with coronary artery disease requiring PCI, whether remote IP reduces: 1) the frequency of myonecrosis; and 2) the inflammatory response to PCI; and 3) whether the effect of IP correlates with pre-procedure circulating endothelial progenitor cell counts.

Methods: The study is a prospective, randomized trial to assess the efficacy of remote IP as adjunctive non-pharmacological therapy for PCI in patients with stable or unstable angina. Remote IP will be performed by 3 cycles of 3-minutes of arm ischemia alternating with 3- minutes of reperfusion of the arm immediately before PCI. Myonecrosis and inflammation will be detected by measuring serum troponin T and high sensitivity C-reactive protein, respectively. Blood EPC counts will also be measured before the procedure.

Enrollment: 156 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients will be eligible for randomization if they meet the following criteria:

  1. Age ≥ 18 years
  2. Clinically indicated elective or urgent PCI

Exclusion criteria

• Patients will be ineligible for the study if one or more of the following conditions exist:

  1. Pre-PCI Troponin T ≥ 0.03
  2. Systemic hypotension (systolic <90 mmHg) or cardiogenic shock
  3. Presence of an arteriovenous fistula or lymphedema of either arm
  4. Currently enrolled in other active cardiovascular investigational studies
  5. Severe endocrine, hepatic, renal, disorders
  6. Pregnancy or lactation
  7. Inability to provide consent
  8. Federal Medical Center inmates
  9. Inability or unwillingness to provide informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

156 participants in 2 patient groups

1

Active Comparator group

Description:

Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes

Treatment:

Device: Blood pressure cuff

2

Sham Comparator group

Description:

3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia

Treatment:

Device: blood pressure cuff